Baidu
map

糖尿病患者缺血性卒中风险或无种族差异

2013-05-06 高晓方 译 医学论坛网

  美国一项研究表明,无论种族如何,糖尿病患者在各年龄段仍表现为卒中风险极大升高,并且在<65岁时尤为显著。论文4月25日在线发表于《卒中》(Stroke)。   既往研究显示在糖尿病患者中缺血性卒中发病率在黑人和白人中升高,尤其是那些年龄<55岁的患者。此项基于人群研究对1993~1994、1999和2005年间年龄≥20岁的黑人和白人中的首次缺血性卒中进行了分析。对性别、种

  美国一项研究表明,无论种族如何,糖尿病患者在各年龄段仍表现为卒中风险极大升高,并且在<65岁时尤为显著。论文4月25日在线发表于《卒中》(Stroke)。

  既往研究显示在糖尿病患者中缺血性卒中发病率在黑人和白人中升高,尤其是那些年龄<55岁的患者。此项基于人群研究对1993~1994、1999和2005年间年龄≥20岁的黑人和白人中的首次缺血性卒中进行了分析。对性别、种族和年龄进行适当校正之后计算发病率。

  结果显示,1993~1994、1999和2005年间,首次缺血性卒中患者中糖尿病病史报告率分别为28%、29%和33%。在黑人中,伴和未伴糖尿病者卒中发病率危险比(RR)由1993~1994的5.6降至2005年的3.2;在白人中上述两个时间段的危险比则均保持在3.8不变。然而,RR随年龄不同有所差异;20~65岁患者中观察到风险总体升高5至14倍。

  英文链接:Diabetes Mellitus

  A Risk Factor for Ischemic Stroke in a Large Bi-Racial Population



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1892571, encodeId=264b18925e116, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun May 26 15:24:00 CST 2013, time=2013-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805964, encodeId=517d18059649e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Mar 20 22:24:00 CST 2014, time=2014-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281150, encodeId=d2f71281150a1, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed May 08 14:24:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353538, encodeId=36a013535385b, content=<a href='/topic/show?id=29e1e4781f1' target=_blank style='color:#2F92EE;'>#种族差异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74781, encryptionId=29e1e4781f1, topicName=种族差异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 08 14:24:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473702, encodeId=88b514e370264, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed May 08 14:24:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1892571, encodeId=264b18925e116, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun May 26 15:24:00 CST 2013, time=2013-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805964, encodeId=517d18059649e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Mar 20 22:24:00 CST 2014, time=2014-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281150, encodeId=d2f71281150a1, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed May 08 14:24:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353538, encodeId=36a013535385b, content=<a href='/topic/show?id=29e1e4781f1' target=_blank style='color:#2F92EE;'>#种族差异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74781, encryptionId=29e1e4781f1, topicName=种族差异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 08 14:24:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473702, encodeId=88b514e370264, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed May 08 14:24:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1892571, encodeId=264b18925e116, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun May 26 15:24:00 CST 2013, time=2013-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805964, encodeId=517d18059649e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Mar 20 22:24:00 CST 2014, time=2014-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281150, encodeId=d2f71281150a1, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed May 08 14:24:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353538, encodeId=36a013535385b, content=<a href='/topic/show?id=29e1e4781f1' target=_blank style='color:#2F92EE;'>#种族差异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74781, encryptionId=29e1e4781f1, topicName=种族差异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 08 14:24:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473702, encodeId=88b514e370264, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed May 08 14:24:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1892571, encodeId=264b18925e116, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun May 26 15:24:00 CST 2013, time=2013-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805964, encodeId=517d18059649e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Mar 20 22:24:00 CST 2014, time=2014-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281150, encodeId=d2f71281150a1, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed May 08 14:24:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353538, encodeId=36a013535385b, content=<a href='/topic/show?id=29e1e4781f1' target=_blank style='color:#2F92EE;'>#种族差异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74781, encryptionId=29e1e4781f1, topicName=种族差异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 08 14:24:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473702, encodeId=88b514e370264, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed May 08 14:24:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1892571, encodeId=264b18925e116, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun May 26 15:24:00 CST 2013, time=2013-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805964, encodeId=517d18059649e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Mar 20 22:24:00 CST 2014, time=2014-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281150, encodeId=d2f71281150a1, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed May 08 14:24:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353538, encodeId=36a013535385b, content=<a href='/topic/show?id=29e1e4781f1' target=_blank style='color:#2F92EE;'>#种族差异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74781, encryptionId=29e1e4781f1, topicName=种族差异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 08 14:24:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473702, encodeId=88b514e370264, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed May 08 14:24:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]

相关资讯

第四届慢病管理大会:健康教育专家面对面

  2013年4月16-17日,第四届中国慢病管理大会在北京国际会议中心隆重召开。17日大会分会场之一设立了一个特别的活动,“慢病健康教育专家面对面”,包括胡大一、洪昭光、向红丁等多位知名健康教育专家在会场现场解答参会代表有关慢病的健康问题。   17日全天的活动中,来自不同领域的专家为现场观众解答了有关高血压、糖尿病、脑血管病、肿瘤、营养等各方面的问题。活动经由各媒体早

Diabetes Care:强化降糖心血管益处仍未显现

  在一项研究中,接受为期9个月强化降糖治疗的老年2型糖尿病患者,其脂联素、脂质、甘油三酯水平有所改善。强化降糖仍未能显示出对患者心血管结局的改善。  原始出处: Koska J, Saremi A, Bahn G, Yamashita S, Reaven PD; for the Veterans Affairs Diabetes Trial Investigators.The Effect

美国糖尿病防治十年进展回顾

  近日发表在《新英格兰医学杂志》(NEJM)上的一项研究表明,1999年-2010年美国糖尿病患者降糖达标率提高了8%,将近12%的患者降压达标,21%的患者LDL胆固醇水平降低。然而33%-49%的患者未能降糖达标,每5例糖尿病患者中就有1例未能戒烟。   研究主要负责人Mohammed Ali医生表示,全美患者对糖尿病的阻击取得了缓慢而有成效的进展。   链接:Achievem

社交网站对健康教育显现影响力

    “脸书”(Facebook)等社交网站对公众健康教育的影响正在显现。   一项研究显示,“脸书”爱用者比例较高的地区,坚持健康生活方式、热爱运动的居民比较多,罹患糖尿病的比例也比较低;而另一些地区的居民,访问的网站大都与热门电视节目相关,这部分人群肥胖与糖尿病比例较高。    

AACE2013糖尿病治疗方案

  AACE日前公布2013年版《糖尿病综合治疗方案》,方便初级保健医生、内分泌科及其他科室医务工作者更好地预防与治疗糖尿病前期与2型糖尿病。   点击下载:AACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2013     

NEJM:糖尿病治疗有进展但仍存不足

  《新英格兰医学杂志》4月25日在线发表的一项研究显示,自1999年以来,成人糖尿病治疗在依从预防措施和控制糖尿病并发症危险因素方面取得了明显进展。然而,仍有半数的患者未达到血糖控制、血压和血脂控制目标,并且半数患者表示未接受过糖尿病教育、常被忽视而未接受推荐的每年1次的疫苗接种、牙科检查和眼部检查(N. Engl. J. Med. 2013;368:16

Baidu
map
Baidu
map
Baidu
map